Tarsons Products Limited
NSE: TARSONSMarket Closed • NSE
Day range
52 week range
Tarsons Products Limited closed at INR320.95 (-2.04%) on volume 0.18x its 20-day average, trading 14.41% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -134.4% QoQ
2024-09-20
DIVIDEND Announced
Annual General Meeting/Dividend - Rs 2 Per Share
2023-07-07
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 6.04x over last 3 years
Risks
Tight Debt Servicing: Interest coverage ratio is under 2.0x
Stretched Valuation: Trading at a high P/E multiple of 153.6x
Bull case
Market Leadership: Established operational scale in Medical Instruments & Supplies.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Dividend | ₹2.00 / share | — | 20 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 07 Jul 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Jul 2022 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
IndiaHealthcare
Is Tarsons Products Limited Shariah compliant?
Tarsons Products Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (23.01%) complies with AAOIFI threshold (≤ 33%).
What is Tarsons Products Limited's current valuation relative to peers?
Tarsons Products Limited trades at a P/E of 153.6x compared to the sector median of 37.6x, and a Price-to-Book of 2.7x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.62x. Interest coverage is 0.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 7.5% while net profit growth averaged -19.6%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.